JP2004536107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536107A5 JP2004536107A5 JP2003510065A JP2003510065A JP2004536107A5 JP 2004536107 A5 JP2004536107 A5 JP 2004536107A5 JP 2003510065 A JP2003510065 A JP 2003510065A JP 2003510065 A JP2003510065 A JP 2003510065A JP 2004536107 A5 JP2004536107 A5 JP 2004536107A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- agent
- subunit
- truncated
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 39
- 239000003795 chemical substances by application Substances 0.000 claims 24
- 108091026890 Coding region Proteins 0.000 claims 15
- 230000001580 bacterial effect Effects 0.000 claims 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 9
- 239000002095 exotoxin Substances 0.000 claims 9
- 231100000776 exotoxin Toxicity 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 102000009016 Cholera Toxin Human genes 0.000 claims 2
- 108010049048 Cholera Toxin Proteins 0.000 claims 2
- 101710146739 Enterotoxin Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 239000000147 enterotoxin Substances 0.000 claims 2
- 231100000655 enterotoxin Toxicity 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000013600 plasmid vector Substances 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 102000009062 ADP Ribose Transferases Human genes 0.000 claims 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims 1
- 101710082714 Exotoxin A Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72431500A | 2000-11-27 | 2000-11-27 | |
| PCT/US2001/043151 WO2003004055A2 (en) | 2000-11-27 | 2001-11-26 | Nucleic acid adjuvants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536107A JP2004536107A (ja) | 2004-12-02 |
| JP2004536107A5 true JP2004536107A5 (enExample) | 2005-12-22 |
| JP4221289B2 JP4221289B2 (ja) | 2009-02-12 |
Family
ID=24909936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003510065A Expired - Fee Related JP4221289B2 (ja) | 2000-11-27 | 2001-11-26 | 核酸アジュバント |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1379273B1 (enExample) |
| JP (1) | JP4221289B2 (enExample) |
| KR (1) | KR20040045391A (enExample) |
| CN (1) | CN1317034C (enExample) |
| AT (1) | ATE442858T1 (enExample) |
| AU (1) | AU2001297988B2 (enExample) |
| BR (1) | BR0115646A (enExample) |
| CA (1) | CA2429708A1 (enExample) |
| DE (1) | DE60139959D1 (enExample) |
| DK (1) | DK1379273T3 (enExample) |
| ES (1) | ES2332261T3 (enExample) |
| IL (2) | IL156041A0 (enExample) |
| MX (1) | MXPA03004638A (enExample) |
| NZ (1) | NZ526175A (enExample) |
| PT (1) | PT1379273E (enExample) |
| WO (1) | WO2003004055A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101225395B1 (ko) | 2003-10-10 | 2013-01-28 | 파우더젝트 백신, 인코포레이티드 | 핵산 구조물 |
| BRPI0507579A (pt) | 2004-02-11 | 2007-07-03 | Angeletti P Ist Richerche Bio | molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| US8389686B2 (en) | 2008-05-07 | 2013-03-05 | Osaka University | Noncovalent collagen crosslinking agent |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CA2848656C (en) | 2010-09-15 | 2017-10-10 | Randall J. Mrsny | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| CN103060253A (zh) * | 2013-01-24 | 2013-04-24 | 麻丽丹 | 霍乱弧菌ctxAB基因的质粒克隆菌株以及制备方法和应用 |
| DK3139965T3 (da) | 2014-05-07 | 2021-11-22 | Applied Molecular Transport Inc | Fusionsmolekyler afledt af cholix-toksin til oral indgivelse af biologisk aktive stoffer |
| EP4082558B1 (en) | 2018-03-08 | 2023-08-23 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| KR20210110294A (ko) | 2018-11-07 | 2021-09-07 | 어플라이드 몰레큘라 트랜스포트 인크. | 통과세포외배출용 전달 구조체 및 관련 방법 |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| GB9416663D0 (en) | 1994-08-17 | 1994-10-12 | Oxford Bioscience Limited | Particle delivery |
| AU3703895A (en) | 1994-10-24 | 1996-05-15 | Oxford Biosciences Limited | Particle delivery |
| GB9426379D0 (en) | 1994-12-23 | 1995-03-01 | Oxford Biosciences Ltd | Particle delivery |
| US6056960A (en) * | 1995-06-07 | 2000-05-02 | Kaslow; Harvey R. | Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
-
2001
- 2001-11-26 ES ES01274277T patent/ES2332261T3/es not_active Expired - Lifetime
- 2001-11-26 AT AT01274277T patent/ATE442858T1/de active
- 2001-11-26 CA CA002429708A patent/CA2429708A1/en not_active Abandoned
- 2001-11-26 NZ NZ526175A patent/NZ526175A/en unknown
- 2001-11-26 JP JP2003510065A patent/JP4221289B2/ja not_active Expired - Fee Related
- 2001-11-26 AU AU2001297988A patent/AU2001297988B2/en not_active Ceased
- 2001-11-26 EP EP01274277A patent/EP1379273B1/en not_active Expired - Lifetime
- 2001-11-26 IL IL15604101A patent/IL156041A0/xx unknown
- 2001-11-26 WO PCT/US2001/043151 patent/WO2003004055A2/en not_active Ceased
- 2001-11-26 KR KR10-2003-7007121A patent/KR20040045391A/ko not_active Ceased
- 2001-11-26 DK DK01274277T patent/DK1379273T3/da active
- 2001-11-26 BR BR0115646-2A patent/BR0115646A/pt not_active Application Discontinuation
- 2001-11-26 PT PT01274277T patent/PT1379273E/pt unknown
- 2001-11-26 CN CNB018195709A patent/CN1317034C/zh not_active Expired - Fee Related
- 2001-11-26 DE DE60139959T patent/DE60139959D1/de not_active Expired - Lifetime
- 2001-11-26 MX MXPA03004638A patent/MXPA03004638A/es active IP Right Grant
-
2003
- 2003-05-21 IL IL156041A patent/IL156041A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1097213B1 (en) | Vaccine against staphylococcus intoxication | |
| ES2139879T5 (es) | Adyuvante de la mucosa no toxico. | |
| US7335369B2 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| US20150266934A1 (en) | Methods for protection against lethal infection with bacillus anthracis | |
| JP2004527213A5 (enExample) | ||
| HU228354B1 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| US20080248068A1 (en) | Use of Flagellin as an Adjuvant for Vaccine | |
| US8834896B2 (en) | Vault compositions for immunization | |
| Wortham et al. | Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2 | |
| JP2004536107A5 (enExample) | ||
| US8143386B2 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| US7064195B2 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| Mohapatra | Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus | |
| JP4875497B2 (ja) | バクテリオファージナノ粒子を含む方法および組成物 | |
| JP2002528123A5 (enExample) | ||
| Delman et al. | Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer | |
| EP1143934B1 (en) | Genetic immunization with co-delivery of nucleic acid and cytokines | |
| EP1954307A2 (en) | Salmonella based oral vaccines for anthrax | |
| TW528760B (en) | Peptide repeat immunogens | |
| CN120500351A (zh) | 呼吸道合胞病毒mRNA疫苗 | |
| US20040082530A1 (en) | Nucleic acid immunization | |
| Xie et al. | Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency | |
| JP6216371B2 (ja) | ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用 | |
| CN111499698B (zh) | 犬i型腺病毒亚单位疫苗及其制备方法 | |
| Dabaghian et al. | Use of N-trimethyl chitosan for intranasal delivery of DNA encoding M2e-HSP70c in mice |